Lv63
2060 积分 2025-05-06 加入
Safety and Tolerability of Low-Dose Radiation and Stereotactic Body Radiotherapy + Sintilimab for Treatment-Naïve Stage IV PD-L1+ Non–Small Cell Lung Cancer Patients
16天前
已完结
464eP Phase II trial of adjuvant sintilimab in lymph node-positive esophageal squamous cell carcinoma (ESCC) after radical surgery without neoadjuvant treatment
21天前
已完结
Neoadjuvant chemotherapy or chemoradiotherapy plus sintilimab versus neoadjuvant chemoradiotherapy for locally advanced oesophageal squamous cell carcinoma: a study protocol of a multicentre, randomised, controlled, phase III trial (SCIENCE study)
21天前
已完结
Sintilimab plus cisplatin and nab‐paclitaxel induction treatment for locally advanced borderline‐resectable oesophageal squamous cell carcinoma: A single‐arm, prospective, phase 2 study (NEOCRTEC2001)
21天前
已完结
First-line tislelizumab plus chemotherapy versus placebo plus chemotherapy in unresectable advanced/metastatic esophageal squamous cell carcinoma: minimum 3-year survival follow-up of a randomized phase 3 trial (RATIONALE-306)
1个月前
已完结
Efficacy and safety of adjuvant sintilimab monotherapy in high-risk resected esophageal squamous cell carcinoma: a prospective, single-arm phase II trial
1个月前
已完结
Significance of the Expression of TC and TG Levels in the Initial Diagnosis and Treatment of SCLC Patients and Their Tie-In with Prognosis
2个月前
已完结
[Epidemiological characteristic and current status of surgical treatment for esophageal cancer by analysis of national registry database]
2个月前
已完结
Retrospective analysis of disease characteristics and treatment patterns among patients with esophageal cancer across 14 surgically represented centers
2个月前
已完结
Definitive chemoradiotherapy combined with anti-PD-1 immunotherapy for inoperable esophageal squamous cell carcinoma: a multicenter real-world study
2个月前
已完结